ALNOV Fundamental Analysis - NOVACYT

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALNOV. ALNOV was compared to 83 industry peers in the Biotechnology industry. While ALNOV seems to be doing ok healthwise, there are quite some concerns on its profitability. ALNOV is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALNOV had negative earnings in the past year.

In the past year ALNOV has reported a negative cash flow from operations.

ALNOV had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: ALNOV reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of ALNOV (-48.32%) is worse than 61.45% of its industry peers.

Looking at the Return On Equity, with a value of -74.44%, ALNOV is in line with its industry, outperforming 50.60% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-48.32%
ROE	-74.44%
ROIC	N/A

ROA(3y)-32.84%

ROA(5y)-9.46%

ROE(3y)-47.33%

ROE(5y)-12.19%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALNOV has a Gross Margin (63.35%) which is in line with its industry peers.

In the last couple of years the Gross Margin of ALNOV has grown nicely.

ALNOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.35%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y75.01%

GM growth 5Y20.62%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALNOV has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for ALNOV has been increased compared to 5 years ago.

The debt/assets ratio for ALNOV is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.56, we must say that ALNOV is in the distress zone and has some risk of bankruptcy.

ALNOV has a Altman-Z score (0.56) which is in line with its industry peers.

ALNOV has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.

ALNOV has a Debt to Equity ratio of 0.24. This is comparable to the rest of the industry: ALNOV outperforms 57.83% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Altman-Z	0.56

ROIC/WACCN/A

WACC6.8%

2.3 Liquidity

ALNOV has a Current Ratio of 5.03. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 5.03, ALNOV is doing good in the industry, outperforming 79.52% of the companies in the same industry.

ALNOV has a Quick Ratio of 4.59. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.

ALNOV's Quick ratio of 4.59 is fine compared to the rest of the industry. ALNOV outperforms 79.52% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.03
Quick Ratio	4.59

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALNOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.85%, which is quite good.

Looking at the last year, ALNOV shows a quite strong growth in Revenue. The Revenue has grown by 8.50% in the last year.

The Revenue has been growing by 11.35% on average over the past years. This is quite good.

EPS 1Y (TTM)17.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%61.73%

Revenue 1Y (TTM)8.5%

Revenue growth 3Y-40.37%

Revenue growth 5Y11.35%

Sales Q2Q%-5.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALNOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALNOV!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVACYT

EPA:ALNOV (12/5/2025, 7:00:00 PM)

0.4545

+0.03 (+6.69%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-30 2025-09-30

Earnings (Next)N/A N/A

Inst Owners0.05%

Inst Owner ChangeN/A

Ins Owners0.06%

Ins Owner ChangeN/A

Market Cap32.10M

Revenue(TTM)19.10M

Net Income(TTM)-30.40M

Analysts37.14

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.47
P/FCF	N/A
P/OCF	N/A
P/B	0.69
P/tB	1.29
EV/EBITDA	N/A

EPS(TTM)-0.5

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.13

FCFYN/A

OCF(TTM)-0.1

OCFYN/A

SpS0.31

BVpS0.66

TBVpS0.35

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.32%
ROE	-74.44%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	63.35%
FCFM	N/A

ROA(3y)-32.84%

ROA(5y)-9.46%

ROE(3y)-47.33%

ROE(5y)-12.19%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y75.01%

GM growth 5Y20.62%

F-Score4

Asset Turnover0.3

Health

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	8.2%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.03
Quick Ratio	4.59
Altman-Z	0.56

F-Score4

WACC6.8%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)5.93%

Cap/Sales(5y)4.53%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)17.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%61.73%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)8.5%

Revenue growth 3Y-40.37%

Revenue growth 5Y11.35%

Sales Q2Q%-5.12%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y33.09%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y56.91%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y65.03%

OCF growth 3YN/A

OCF growth 5YN/A

NOVACYT / ALNOV.PA FAQ

What is the ChartMill fundamental rating of NOVACYT (ALNOV.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALNOV.PA.

What is the valuation status for ALNOV stock?

ChartMill assigns a valuation rating of 0 / 10 to NOVACYT (ALNOV.PA). This can be considered as Overvalued.

Can you provide the profitability details for NOVACYT?

NOVACYT (ALNOV.PA) has a profitability rating of 1 / 10.

How financially healthy is NOVACYT?

The financial health rating of NOVACYT (ALNOV.PA) is 4 / 10.

NOVACYT (ALNOV.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NOVACYT / ALNOV.PA FAQ

What is the ChartMill fundamental rating of NOVACYT (ALNOV.PA) stock?

What is the valuation status for ALNOV stock?

Can you provide the profitability details for NOVACYT?

How financially healthy is NOVACYT?